EWAS can significantly enhance risk assessment by identifying biomarkers of exposure and early biological effects that precede overt disease. These biomarkers can be used to improve the detection of at-risk populations and to develop targeted interventions. Furthermore, understanding the epigenetic mechanisms underlying toxicant exposure can inform regulatory decisions and guide the development of safer chemicals and drugs.
